Novel neutralising antibodies targeting the N-terminal helical region of the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV)

Immunologic Research

Volumn 58, Issue 1, 2014, Pages 9-19

  Waechter, Alexander ^a   Denner, Joachim ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Neutralising antibodies; Porcine endogenous retrovirus (PERV); Retroviruses; Xenotransplantation

Indexed keywords

FREUND ADJUVANT; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; TRANSMEMBRANE ENVELOPE PROTEIN P15E; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY ISOLATION; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; C TERMINAL HELICAL REGION; CAPRINE MODEL; CELL STRAIN HEK293; CONTROLLED STUDY; CYS CYS LOOP; ENDOGENOUS RETROVIRUS; EPITOPE MAPPING; EXPERIMENTAL GOAT; EXPERIMENTAL RABBIT; FUSION PEPTIDE PROXIMAL REGION; HUMAN; HUMAN CELL; IMMUNIZATION; N TERMINAL HELICAL REGION; NONHUMAN; POINT MUTATION; PORCINE ENDOGENOUS RETROVIRUS; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ENDOGENOUS RETROVIRUSES; EPITOPE MAPPING; GOATS; IMMUNIZATION; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NEUTRALIZATION TESTS; RABBITS; RECOMBINANT PROTEINS; RETROVIRIDAE INFECTIONS; SWINE; SWINE DISEASES; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84893745270     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8430-y     Document Type: Article

References (45)

1. Denner J, Tönjes RR. Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses. Clin Microbiol Rev. 2012;25(2):318-43.
2. Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med. 1997;3:282-6.
3. Le Tissier P, Stoye JP, Takeuchi Y, Patience C, Weiss RA. Two sets of human-tropic pig retrovirus. Nature. 1997;389:681-2.
4. Takeuchi Y, Patience C, Magre S, Weiss RA, Banerjee PT, Le Tissier P, Stoye JP. Host range and interference studies of three classes of pig endogenous retrovirus. J Virol. 1998;72:9986-91.
5. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature. 1999;397:436-41.
6. Tarlinton R, Meers J, Young P. Biology and evolution of the endogenous koala retrovirus. Cell Mol Life Sci. 2008;65:3413-21.
7. Fiebig U, Stephan O, Kurth R, Denner J. Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation? Virology. 2003;307:406-13.
8. Kaulitz D, Fiebig U, Eschricht M, Wurzbacher C, Kurth R, Denner J. Generation of neutralising antibodies against porcine endogenous retroviruses (PERVs). Virology. 2011;411:78-86.
9. Denner J, Mihica D, Kaulitz D, Schmidt CM. Increased titers of neutralizing antibodies after immunization with both envelope proteins of the porcine endogenous retroviruses (PERVs). Virology J. 2012;9:260.
10. Langhammer S, Fiebig U, Kurth R, Denner J. Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV). Vaccine. 2005;23:3341-8.
11. Langhammer S, Hubner J, Kurth R, Denner J. Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E. Immunology. 2006;117:229-37.
12. Langhammer S, Hubner J, Jarrett O, Kurth R, Denner J. Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: absence of antigenemia following challenge. Antiviral Res. 2011;89:119-23.
13. Langhammer S, Fiebig U, Kurth R, Denner J. Increased neutralizing antibody response after simultaneous immunization with leucogen and the feline leukemia virus transmembrane protein. Intervirology. 2011;54:78-86.
14. Fiebig U, Hartmann MG, Bannert N, Kurth R, Denner J. Transspecies transmission of the endogenous koala retrovirus. J Virol. 2006;80:5651-4.
15. Waechter A, Eschricht M, Denner J. Neutralisation of the porcine endogenous retrovirus (PERV) by antibodies against the transmembrane envelope protein. J Gen Virol. 2012/2013;94(Pt 3):643-51.
16. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993;67:6642-7.
17. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol. 2001;75:10892-905.
18. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;15:491(7424):406-12.
19. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, Blumenthal R. The HIV Env-mediated fusion reaction. Biochim Biophys Acta. 2003;1614:36-50.
20. Bellamy-McIntyre AK, Lay CS, Baar S, Maerz AL, Talbo GH, Drummer HE, Poumbourios P. Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J Biol Chem. 2007;282:23104-16.
21. de la Arada I, Julien JP, de la Torre BG, Huarte N, Andreu D, Pai EF, Arrondo JL, Nieva JL. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5. J Phys Chem B. 2009;113:13626-37.
22. Denner J. Towards an AIDS vaccine: the transmembrane envelope protein as target for broadly neutralizing antibodies. Human Vaccines. 2011;7Suppl:4-9.
23. Schagger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987;166:368-79.
24. Denner J, Specke V, Thiesen U, Karlas A, Kurth R. Genetic alterations of the long terminal repeat of an ecotropic porcine endogenous retrovirus during passage in human cells. Virology. 2003;314:125-33.
25. Huarte N, Lorizate M, Perez-Paya E, Nieva JL. Membrane-transferring regions of gp41 as targets for HIV-1 fusion inhibition and viral neutralization. Current Top Med Chem. 2011;11:2985-96.
26. Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, Polonis VR, Alving CR. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS. 2009;23:2069-77.
27. Wang J, Tong P, Lu L, Zhou L, Xu L, Jiang S, Chen YH. HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. PLoS ONE. 2011;6:e18233.
28. Luo M, Yuan F, Liu Y, Jiang S, Song X, Jiang P, Yin X, Ding M, Deng H. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment. Vaccine. 2006;24:435-42.
29. Denner J. Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: A comparative study. Hum Vaccin Immunother. 2012;18:9(3).
30. Lorizate M, de la Arada I, Huarte N, Sanchez-Martinez S, de la Torre BG, Andreu D, Arrondo JL, Nieva JL. Structural analysis and assembly of the HIV-1 Gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at- interface sequence. Biochemistry. 2006;45:14337-46.
31. Noah E, Biron Z, Naider F, Arshava B, Anglister J. The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide. Biochemistry. 2008;47:6782-92.
32. Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010;6:e1000880.
33. Lorizate M, Gómara MJ, de la Torre BG, Andreu D, Nieva JL. Membrane-transferring sequences of the HIV-1 Gp41 ectodomain assemble into an immunogenic complex. J Mol Biol. 2006;360:45-55.
34. Fiebig U, Schmolke M, Eschricht M, Kurth R, Denner J. Mode of interaction between the HIV-1-neutralizing monoclonal antibody 2F5 and its epitope. AIDS. 2009;23(8):887-95.
35. Gustchina E, Li M, Louis JM, Anderson DE, Lloyd J, Frisch C, Bewley CA, Gustchina A, Wlodawer A, Clore GM. Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41. PLoS Pathog. 2010;6:e1001182.
36. Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, Zhang H, Lu M, An Z, Ingallinella P, Finotto M, Mattu M, Finnefrock AC, Bramhill D, Cook J, Eckert DM, Hampton R, Patel M, Jarantow S, Joyce J, Ciliberto G, Cortese R, Lu P, Strohl W, Schleif W, McElhaugh M, Lane S, Lloyd C, Lowe D, Osbourn J, Vaughan T, Emini E, Barbato G, Kim PS, Hazuda DJ, Shiver JW, Pessi A. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci USA. 2005;102:14759-64.
37. Sabin C, Corti D, Buzon V, Seaman MS, Lutje Hulsik D, Hinz A, Vanzetta F, Agatic G, Silacci C, Mainetti L, Scarlatti G, Sallusto F, Weiss R, Lanzavecchia A, Weissenhorn W. Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog. 2010;6:e1001195.
38. Nelson JD, Kinkead H, Brunel FM, Leaman D, Jensen R, Louis JM, Maruyama T, Bewley CA, Bowdish K, Clore GM, Dawson PE, Frederickson S, Mage RG, Richman DD, Burton DR, Zwick MB. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology. 2008;377:170-83.
39. Montgomery DL, Wang YJ, Hrin R, Luftig M, Su B, Miller MD, Wang F, Haytko P, Huang L, Vitelli S, Condra J, Liu X, Hampton R, Carfi A, Pessi A, Bianchi E, Joyce J, Lloyd C, Geleziunas R, Bramhill D, King VM, Finnefrock AC, Strohl W, An Z. Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs. 2009;1:462-74.
40. Luftig MA, Mattu M, Di Giovine P, Geleziunas R, Hrin R, Barbato G, Bianchi E, Miller MD, Pessi A, Carfi A. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nature Struct Mol Biol. 2006;13:740-7.
41. Eckert DM, Kim PS. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci USA. 2001;98:11187-92.
42. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, Willems B, Zekveld MJ, Dreja H, O'Sullivan E, Pade C, Orkin C, Jeffs SA, Montefiori DC, Davis D, Weissenhorn W, McKnight A, Heeney JL, Sallusto F, Sattentau QJ, Weiss RA, Lanzavecchia A. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE. 2010;5:e8805.
43. Qi Z, Pan C, Lu H, Shui Y, Li L, Li X, Xu X, Liu S, Jiang S. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice. Biochem Biophys Res Commun. 2010;398:506-12.
44. Frey G, Chen J, Rits-Volloch S, Freeman MM, Zolla-Pazner S, Chen B. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat Struct Mol Biol. 2010;17:1486-91.
45. Hrin R, Montgomery DL, Wang F, Condra JH, An Z, Strohl WR, Bianchi E, Pessi A, Joyce JG, Wang YJ. Short communication: in vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. AIDS Res Human Retroviruses. 2008;24:1537-44.